Get the Stockscreener App
172.00
0.77%
-1.33
After Hours:
172.00
Overview
News
Price History
Option Chain
Financials
Why DHR Down?
Discussions
Forecast
Stock Split
Dividend History
Danaher Corp stock is traded at $172.00, with a volume of 2.99M.
It is down -0.77% in the last 24 hours and down -6.54% over the past month.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
See More
Previous Close:
$173.33
Open:
$173.54
24h Volume:
2.99M
Relative Volume:
0.68
Market Cap:
$121.74B
Revenue:
$24.78B
Net Income/Loss:
$3.68B
P/E Ratio:
33.24
EPS:
5.1743
Net Cash Flow:
$5.29B
1W Performance:
+6.23%
1M Performance:
-6.54%
6M Performance:
-24.36%
1Y Performance:
-8.26%
1-Day Range:
$171.14
$174.95
1-Week Range:
$161.23
$174.95
52-Week Range:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Name
Danaher Corp
Sector
Industry
Phone
(202) 828-0850
Address
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Goldman | Buy |
| Dec-02-25 | Initiated | Morgan Stanley | Overweight |
| Oct-08-25 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Apr-10-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Mar-14-25 | Upgrade | Stifel | Hold → Buy |
| Feb-03-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Dec-19-24 | Initiated | Guggenheim | Buy |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-31-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-18-23 | Initiated | HSBC Securities | Hold |
| Dec-13-23 | Resumed | Wolfe Research | Peer Perform |
| Dec-07-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-01-23 | Initiated | SVB Securities | Outperform |
| Apr-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-18-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-05-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Oct-24-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-17-22 | Resumed | Bernstein | Outperform |
| Jul-20-22 | Initiated | UBS | Buy |
| Jun-01-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-11-22 | Initiated | Bernstein | Outperform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-10-21 | Reiterated | BofA Securities | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Reiterated | Goldman | Buy |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Apr-07-21 | Resumed | Robert W. Baird | Outperform |
| Mar-03-21 | Resumed | Barclays | Overweight |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-25-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jun-16-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-02-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-26-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-03-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Resumed | Stifel | Hold |
| Oct-28-19 | Reiterated | Needham | Buy |
| Oct-14-19 | Resumed | Credit Suisse | Outperform |
| Jul-19-19 | Reiterated | Needham | Buy |
| Jun-11-19 | Initiated | Piper Jaffray | Neutral |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| Apr-17-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Reiterated | Needham | Buy |
| Feb-25-19 | Upgrade | Janney | Neutral → Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Apr-20-18 | Reiterated | Stifel | Buy |
View All
Danaher Corp Stock (DHR) Latest News
Masimo earnings in focus as Danaher deal nears close - Investing.com
Danaher Corp. May Be the Smartest Bet in Biotech Right Now - AOL.com
Danaher Raises $3 Billion in Record Private-Placement Bond Sale - Bloomberg.com
Danaher Targets Carbon Capture And AI CMC To Shape Long Term Growth - Yahoo Finance
Danaher stock (US2358511028): diagnostics spin?off and Q1 earnings reshape the portfolio - AD HOC NEWS
Danaher Corp. stock (US2358511028): earnings beat keeps focus on life sciences recovery - AD HOC NEWS
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
Eagle Capital Management Bet on Danaher (DHR) for Its Mid-Teens EPS Growth - Yahoo Finance
Tissue Diagnostics Market to Reach USD 9.33 Bn by 2031 Driven by Expanding Precision Oncology Applications and Rising Adoption of Digital Pathology, Says Mordor Intelligence - GlobeNewswire Inc.
Danaher stock (US2358511028): spin-off, diagnostics focus and what the latest numbers reveal - AD HOC NEWS
Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead? - The Globe and Mail
Pall to Address a Key Decarbonization Challenge with Additively Manufactured Filtration - PR Newswire
Why The Narrative Around Danaher (DHR) Is Shifting With Bioprocess Recovery And Masimo Deal - Yahoo Finance
Danaher Corp. stock (US2358511028): insider awards highlight leadership confidence after guidance li - AD HOC NEWS
Danaher (NYSE: DHR) director Linda Filler receives stock and option grants - Stock Titan
Danaher (NYSE: DHR) SVP uses 281 shares for tax withholding, retains 8,291 - Stock Titan
[Form 4] DANAHER CORP /DE/ Insider Trading Activity - Stock Titan
Alan G. Spoon (DHR) awarded RSUs and stock options in new Danaher Form 4 - Stock Titan
Danaher (NYSE: DHR) director awarded RSUs and long-dated stock options - Stock Titan
Danaher (NYSE: DHR) director Teri List granted RSUs and stock options as board compensation - Stock Titan
Danaher (NYSE: DHR) awards director Zerhouni RSUs and stock options - Stock Titan
Danaher (NYSE: DHR) director granted RSUs and options in new award - Stock Titan
Danaher (DHR) director Charles Lamanna awarded RSUs and 1,699-share option - Stock Titan
Danaher shares climb as analysts turn more constructive after Q1 guidance lift - Quiver Quantitative
Danaher Corp. stock (US2358511028): restructuring after spin-off, new focus on life sciences - AD HOC NEWS
Northwestern Mutual Wealth Management Co. Acquires 186,584 Shares of Danaher Corporation $DHR - MarketBeat
Danaher stock (US2358511028): Q1 figures, dividend and analyst views in focus - AD HOC NEWS
Danaher stock (US2358511028): earnings momentum and dividend in focus for US investors - AD HOC NEWS
Masimo Corp stock (US5747951003): earnings, Danaher deal and what’s next for the medical-tech spec - AD HOC NEWS
Solid Q1 and Guidance Underlines Why Danaher Corporation (DHR) is one of Steve Cohen’s Large-Cap Stock Picks - Insider Monkey
Danaher Masimo Deal Shifts Growth Outlook And Investor Focus - Yahoo Finance
DoorDash Inc stock (US2358511028): Q1 2026 profit beat keeps growth story in focus - AD HOC NEWS
Danaher Corporation Trade Ideas — AQUISEU:DAPD - TradingView
Danaher Valuation Reset Highlights Recurring Revenues And Lean Operating Framework - Yahoo Finance
Danaher Seen on Path to Growth Reacceleration on Bioprocess Recovery, RBC Says - marketscreener.com
DHR Reinstated by RBC Capital -- Price Target Set at $200 - GuruFocus
Danaher Stock: Analyst Estimates & Ratings - Barchart
Danaher stock (US2358511028): spin-offs reshape the medtech group after latest quarterly numbers - AD HOC NEWS
Danaher (DHR) Receives Outperform Rating from RBC Capital with $200 Price Target - GuruFocus
RBC Capital assumes Danaher stock coverage with outperform rating - Investing.com UK
RBC Capital assumes Danaher stock coverage with outperform rating By Investing.com - Investing.com Nigeria
DoorDash Inc stock (US2358511028): investors weigh latest results and US food delivery outlook - AD HOC NEWS
Jim Cramer Discusses the Performance of Danaher and Its Peers - Insider Monkey
Danaher stock (US2358511028): Shares decline amid four-day losing streak - AD HOC NEWS
The Escalator: Rx&O, Danaher, Ruder Finn and more - Medical Marketing and Media
Transcript : Danaher Corporation Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 11 - marketscreener.com
Is Danaher Corporation (DHR) A Good Stock To Buy Now? - Yahoo Finance
Jim Cramer’s Take on 5 Stocks: Home Depot, Procter & Gamble, and Danaher - Insider Monkey
Cepheid Receives CE Marking Under IVDR for Xpert® GI Panel | Newswise - Newswise
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Danaher stock (US2358511028): Shares slide as institutional holdings shift - AD HOC NEWS
Danaher Corp Stock (DHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):